Osimertinib Mesylate | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Osimertinib Mesylate
Health Canada Patents

Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

Contact Supplier

Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

Contact Supplier

xyz-pharma-m-2025-03-24

Contact Supplier

PharmaCompass Sponsored Ads

Contact Supplier

Gentec Pharmaceutical Group is focused on manufacturing & developing APIs/HPAPIs, Advanced Intermediates & Fine Chemicals.

Contact Supplier

xyz-pharma-m-2025-03-17

Contact Supplier

Osimertinib Mesylate

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

22 API Suppliers, 4 USDMF, 4 EU WC, 8 KDMF, 5 NDC API, 19 Listed Suppliers, $ API Reference Price

22 API Suppliers
4 USDMF
4 EU WC
8 KDMF
5 NDC API
19 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

61 Drugs in Development

61 Drugs in Development

INTERMEDIATES

45 Intermediate Suppliers

45 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

26 FDF Dossiers, 4 FDA Orange Book, 6 Europe, 2 Canada, 6 Australia, 2 South Africa, 6 Listed Dossiers

26 FDF Dossiers
4 FDA Orange Book
6 Europe
2 Canada
6 Australia
2 South Africa
6 Listed Dossiers

DIGITAL CONTENT

1 Data Compilation #PharmaFlow, 2 Stock Recap #PipelineProspector, 147 News #PharmaBuzz

1 Data Compilation #PharmaFlow
2 Stock Recap #PipelineProspector
147 News #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 4 Regulatory FDF Prices, 9 Annual Reports

1 US Medicaid Prescriptions
4 Regulatory FDF Prices
9 Annual Reports

MARKET PLACE

7 APIs, 2 FDF Dossiers

7 APIs
2 FDF Dossiers

PATENTS & EXCLUSIVITIES

32 US Patents, 8 US Exclusivities, 2 Health Canada Patents

32 US Patents
8 US Exclusivities
2 Health Canada Patents

$ API Ref.Price (USD/KG) : 14,327 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

2 All

01 2AstraZeneca Canada Inc.

filter Patent Reset all filters

2 All

01 22843109

filter Product Reset all filters

2 All

01 2OSIMERTINIB MESYLATE

filter Dosage Reset all filters

2 All

01 2TABLET

filter Exp Date Reset all filters

2 All

01 22032-07-25

Product Main Page

01

AstraZeneca Canada Inc.

Osimertinib Mesylate

Immuno-Oncology 360

Not Confirmed

AstraZeneca Canada Inc.

Immuno-Oncology 360

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2032-07-25

Date Granted : 2015-06-16

Osimertinib Mesylate

Brand Name : TAGRISSO

Patent Number : 2843109

Filing Date : 2012-07-25

Strength per Unit : 40mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2032-07-25

Date Granted : 2015-06-16

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

AstraZeneca Canada Inc.

Osimertinib Mesylate

Immuno-Oncology 360

Not Confirmed

AstraZeneca Canada Inc.

Immuno-Oncology 360

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2032-07-25

Date Granted : 2015-06-16

Osimertinib Mesylate

Brand Name : TAGRISSO

Patent Number : 2843109

Filing Date : 2012-07-25

Strength per Unit : 80mg

Dosage Form : TABLET

Human Or VET : Human

Route of Administration : ORAL

Patent Expiration Date : 2032-07-25

Date Granted : 2015-06-16

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
Ask Us!